Testing how long to take PD-1 therapy for melanoma
Part of Cancer, Skin clinical trials.
This trial studies whether people with metastatic melanoma should take PD-1 immunotherapy continuously or only for a limited time. It aims to find a schedule that keeps the cancer under control while possibly reducing treatment burden.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and eligible for publicly funded PD-1 treatment in your province
- Have melanoma that has spread or cannot be removed by surgery (stage III/IV)
- Be starting this study soon after beginning PD-1 treatment (or soon before), and have a recent scan to confirm no new progression
- Be able and willing to fill out quality-of-life and health questionnaire forms in English or French
- Be willing to follow the study’s treatment schedule—especially stopping PD-1 if you’re assigned to intermittent dosing
- If you have brain metastases, they must be stable (no recent growth or new lesions) before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This trial tests if an immunotherapy drug (anti-PD1) can change atypical (dysplastic) moles in people who have had melanoma. It may help understand how these drugs affect mole cells.
This trial tests a new drug, OPM-101, combined with an immunotherapy drug (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Unresectable/Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.